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ABSTRACT
Phosphoinositide-3-kinase (PI3K) is an enzyme group, known to regulate key 
survival pathways in acute myeloid leukaemia (AML). It generates phosphatidylinositol-
3,4,5-triphosphate, which provides a membrane docking site for protein kinaseB 
activation. PI3K catalytic p110 subunits are divided into 4 isoforms; α,β,δ and γ. The 
PI3Kδ isoform is always expressed in AML cells, whereas the frequency of PI3Kγ 
expression is highly variable. The functions of these individual catalytic enzymes have 
not been fully resolved in AML, therefore using the PI3K p110δ and p110γ-targeted 
inhibitor IPI-145 (duvelisib) and specific p110δ and p110γ shRNA, we analysed the 
role of these two p110 subunits in human AML blast survival. The results show that 
PI3Kδ and PI3Kγ inhibition with IPI-145 has anti-proliferative activity in primary 
AML cells by inhibiting the activity of AKT and MAPK. Pre-treatment of AML cells with 
IPI-145 inhibits both adhesion and migration of AML blasts to bone marrow stromal 
cells. Using shRNA targeted to the individual isoforms we demonstrated that p110δ-
knockdown had a more significant anti-proliferative effect on AML cells, whereas 
targeting p110γ-knockdown significantly inhibited AML migration. The results 
demonstrate that targeting both PI3Kδ and PI3Kγ to inhibit AML-BMSC interactions 
provides a biologic rationale for the pre-clinical evaluation of IPI-145 in AML.
INTRODUCTION
Although clinically, morphologically and 
biologically acute myeloid leukaemia (AML) appears 
to represent a heterogeneous group of diseases, the 
disease seems to rely on common intra-cellular survival 
and self-renewal pathways downstream of the driver 
oncogene [1]. It is envisaged that inhibition of common 
dysregulated signalling pathways in AML would result in 
novel treatment strategies in the future. Tyrosine kinases 
(TKs) are an attractive potential target in AML, having 
been shown to be effective drugable targets in other types 
of leukaemia [2-4]. Moreover, receptor TKs (RTKs) 
are mutated in approximately 50% of all patients with 
AML [5, 6]. Furthermore, cell survival and proliferation 
pathways dependent on TK activation, including MAPK; 
phosphoinositide 3-kinase (PI3K)/AKT; mTOR; NF-κB 
and STATs are deregulated in most, if not all, cases of 
AML [7–10].
PI3K is an enzyme group that generates 
phosphatidylinositol 3, 4, 5-triphosphate which provides 
a membrane docking site for the serine-threonine kinase 
Protein Kinase B (PKB), also known as AKT [8]. Many 
of the downstream effects of PI3K are mediated through 
AKT, which interacts with further downstream signalling 
molecules, which in turn regulate cell proliferation, cell 
migration and cell adhesion [8, 11]. It has been observed 
that activation of the PI3K/AKT pathway is present in over 
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60% of AML patients and is associated with decreased 
overall survival [12, 13]. The mechanisms leading to PI3K 
activation in AML, however presently remain unclear.
Class I PI3K catalytic p110 subunits are divided into 
4 isoforms; α, β, δ and γ. Within the p110 catalytic subunit 
the p110δ isoform is always expressed in AML cells [14, 
15]. Conversely the p110γ, p110α and p110β isoforms are 
heterogeneously expressed [16, 17]. PI3K has previously 
been reported to be downstream of survival, proliferation, 
adhesion and migration signals including CD117, FLT3, 
VLA4 and CXCR4 in a spectrum of benign and malignant 
haematopoietic cells [11, 18, 19]. In AML these signals 
play an important role in tumour survival. However, 
little is known about the role of PI3K in regulating bone 
marrow-derived AML survival signals.
RESULTS
PI3K inhibition reduces the survival of AML 
blasts
To determine the level of detectable PI3Kδ and 
PI3Kγ in AML we examined five AML cell lines and eight 
primary AML samples. Figure 1A shows the expression 
profile of PI3Kδ and PI3Kγ in AML cell lines and AML 
primary blasts. Figure 1B shows the expression profile 
of PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ in normal CD34+ 
cells and AML primary blasts. However, we observed 
variations in the level of detection between different cell 
lines and different primary AML samples: this is thought 
to be due to high heterogeneity within AML. Next we 
wanted to examine the effects of targeting PI3Kδ and 
PI3Kγ in AML. To do this we first assessed the effect of 
various PI3K inhibitors including LY294002 (pan-PI3K 
inhibitor, which is not suitable for clinical use as it is toxic 
in vivo [20]) with a concentration of 25µM [21], CAL-
101 (Idelalisib - PI3Kδ inhibitor, which has been found to 
have a physiologically relevant concentration of between 
0.3-1µM [22]) and IPI-145 (PI3Kδ and PI3Kγ inhibitor, 
which has a physiologically relevant concentration of 1µM 
[23]) on AML cell lines. We treated AML cell lines with 
each drug and incubated them for 72hrs. Figure 1C shows 
that LY294002, IPI-145 and CAL-101 treatment resulted 
in a decrease in AML cell survival. Next we examined 
the effect of increasing concentrations of IPI-145 on 
AML blast survival. Figure 1D shows that all AML cell 
lines had a dose-dependent reduction in cell survival to 
increasing concentrations of IPI-145 after culture for 48 
hours. Subsequently we examined the effect of IPI-145 
treatment on primary AML blasts. Figure 1E shows that 
primary AML blast survival is reduced in response to 
increasing concentrations of IPI-145, after culture for 48 
hours. Finally we examined the effect of IPI-145 on AML 
blast colony formation in methylcellulose. AML samples 
were sensitive to the effects of IPI-145 at concentrations 
of 1000nM (Figure 1F). Figure 1G shows that the AKT 
inhibitor, MK2206 and IPI-145 can induce apoptosis in 
AML cells. Together we report that PI3Kδ and PI3Kγ 
are constitutively expressed in all AML samples tested 
and that specific inhibition of these isoforms in AML 
significantly reduces survival and colony formation. 
Importantly, this can be achieved at physiologically 
relevant concentrations of IPI-145 [24, 25].
IPI-145 inhibits AKT phosphorylation in AML 
cell lines and primary AML blasts
The next step was to determine the effect of PI3Kδ 
and PI3Kγ inhibition on AKT activation. AML cell 
lines and primary tissue were treated with increasing 
concentrations of IPI-145 and cultured for 4 hours before 
Western blot analysis was performed. PI3Kδ and PI3Kγ 
inhibition showed a reduction in AKT phosphorylation 
at serine 473 (s473) in all AML cell lines and primary 
AML tested. There was also a dose dependent reduction 
in MAPK phosphorylation in response to IPI-145 in 
OCI-AML3, MV4-11 cell lines (Figure 2A) and primary 
AML blasts (AML#2 and AML#5) (Figure 2B). These 
results demonstrate that PI3Kδ and PI3Kγ inhibition 
with IPI-145 inhibits downstream signalling through 
AKT phosphorylation at the s473 and t308 and MAPK 
phosphorylation sites. One primary sample (AML#5) 
used in this assay did not express constitutive AKT 
phosphorylation at t308 so no inhibition of this activity 
was observed in these cells. Figure 2C shows the effect of 
IPI-145, MK2206 (AKT inhibitor) and AZD6244 (MAPK 
inhibitor) on three AML samples.
IPI-145 inhibits adhesion of AML blasts to 
primary BMSC
The microenvironment is an essential component 
underpinning survival of AML blasts. Inhibiting AML 
blast adhesion to BMSCs via VLA4-VCAM/fibronectin 
interactions via the PI3K/AKT signalling pathway is 
associated with improvements in chemotherapy-induced 
tumour cytotoxicity [26]. Therefore, to determine 
whether PI3Kδ and PI3Kγ inhibition with IPI-145 
could overcome BMSC-AML mediated adhesion, AML 
cell lines and primary AML blasts were treated with 
increasing concentrations of IPI-145. Figure 3A and 
3B show that PI3Kδ and PI3Kγ inhibition with IPI-145 
inhibits AML cell line(s) and primary blast adhesion to 
the BMSC. Next we examined if IPI-145, CAL101 and 
MK2206 could disrupt AML binding to BMSC (Figure 
3C). Figure 3D shows that binding of three AML cell 
lines to fibronectin was disrupted by IPI-145. Finally we 
wanted to determine if IPI-145 could impair AML chemo-
resistance derived from the BMSC. Primary AML had a 
higher viability when incubated on BMSC or fibronectin 
(Figure 3E and 3F) compared to uncoated plates in the 
presence of daunorubicin 0.1µM (DNR) and cytarabine 
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Figure 1: Targeting PI3K inhibits AML survival in AML cell lines and primary AML blasts. A. AML cell lines and AML 
patient cells were measured for constitutive levels of PI3Kδ and PI3Kγ by Western blotting, blots reprobed for β-actin to show sample 
loading. B. AML patient cells and CD34+ cells were measured for constitutive levels of PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ by Western 
blotting, blots reprobed for β-actin to show sample loading. C. AML cell lines were treated with 25 μM LY294002, 10μM CAL-101 or 10 
μM IPI-145 and cultured for 72 hours and then assessed by CellTiterGlo. D. AML cell lines were treated with increasing concentrations 
of IPI-145 and cultured for 48 hours and then cell viability was assessed by CellTiterGlo. E. Primary AML blasts were treated with 
increasing concentrations of IPI-145 and incubated for 48 hours and then assessed by CellTiterGlo. F. AML blasts, AML cell lines and 
CD34+ control cells were treated with 1000nM of IPI-145 and colony forming assays were performed to show the number of colonies. G. 
Primary AML blasts were treated with MK2206 (1000nM), IPI-145 (1000nM) for 48 hours and then analysed for apoptosis using annexin 
V and PI staining. * indicates those results which are statistically significant using the Mann-Whitney U test (P-value <0.05), looking at the 
comparison between the control and treatment groups.
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Figure 2: IPI-145 inhibits AKT phosphorylation in AML. A. and B. AML cell lines and primary AML blasts were treated with 
increasing doses of IPI-145 (nM) and cultured for 4 hours. Whole cell extracts were prepared and Western blot analysis was conducted 
for pAKT, pMAPK, and total AKT and MAPK protein levels. C. AML blasts were treated with IPI-145 (1000nM), MK2206 (1000nM) 
and AZD6244 (1000nM) and cultured for 4 hours. Whole cell extracts were prepared and Western blot analysis was conducted for pAKT, 
pMAPK, and total AKT and MAPK protein levels.
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Figure 3: IPI-145 inhibits adhesion of AML blasts to primary BMSC. A. and B. AML cell lines and primary AML blasts 
(AML#1, AML#2 and AML#3) were treated with increasing doses of IPI-145 and cultured for 16 hours. Calcein-AM was added at 2.5μM 
for 1 hour, then washed off. The cells were then cultured on top of primary BMSC for 4 hours. Non-adherent cells were taken off with gentle 
washing. Adherent cells were measured using a fluorescence plate reader. Cell adhesion was then assessed and expressed as percentage of 
total cells in the assay. C. Primary AML were treated with 500nM of IPI-145, 1000nM CAL-101, and 1000nM MK2206. The cells were 
then cultured on top of primary BMSC for 4h. Non-adherent cells were taken off with gentle washing. Cell adhesion was then assessed and 
expressed as percentage of total cells in the assay. D. AML cell lines were treated with increasing doses of IPI-145 and cultured for 4 hours. 
Calcein-AM was added at 2.5μM for 1 hour, then washed off. The cells were then cultured on fibronectin (FN) coated plates. Non-adherent 
cells were taken off with gentle washing. Adherent cells were measured using a fluorescence plate reader. Cell adhesion was then assessed 
and expressed as percentage of total cells in the assay. E. Primary AML blasts were incubated alone (light grey) or on BMSC (dark grey). 
The samples were then pretreated with DMSO or IPI-145 (500nM) followed by daunorubicin (100nM) (DNR) or cytarabine (500nM) 
(ARA-c). Live AML blasts cells were counted using trypan blue exclusion. F. Primary AML blasts were incubated alone (light grey) or on 
fibronectin (FN) (dark grey). The samples were then pretreated with DMSO or IPI-145 (500nM) followed by daunorubicin (100nM) (DNR) 
or cytarabine (500nM) (ARA-c). Live AML blasts cells were counted using trypan blue exclusion. Significance for E. and F. between 
IPI-145 treated and control treated samples when cultured with or without BMSC or FN was determined using the two-way ANOVA with 
Sidak’s post test. Results with P < 0.05 were considered statistically significant (*).
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0.5µM (ARA-c), both of which are conventional 
chemotherapeutic agents used in AML. Pre-treatment 
of 3 AML samples with IPI-145 (500nM) nullified the 
difference between AML cells incubated on BMSC or 
fibronectin and those incubated on uncoated plates (Figure 
3E and 3F). These results imply that AML chemotherapy 
resistance (to daunorubicin and cytarabine) conferred 
by BMSC is able to be overcome by PI3Kδ and PI3Kγ 
inhibition in combination with these chemotherapy agents.
IPI-145 inhibits AML migration
In order to determine whether PI3Kδ and PI3Kγ 
inhibition can disrupt AML migration we undertook assays 
using BMSC conditioned media (CM) as a migration 
stimulus and normal media (NM) as a control. Figure 4A 
shows that primary AML blasts migrate towards BMSC 
CM, which is inhibited by the addition of 500nM IPI-
145, which is consistent with the concentrations we have 
used throughout this study. PI3Kγ has been reported to 
regulate migration signals via G-protein coupled receptor 
(GPCR) activation in monocytes and macrophages [27]. In 
addition, GPCR activation has been shown to signal via the 
phosphorylation of AKT [28]. Therefore we examined the 
effect of IPI-145 on AKT s473 and t308 phosphorylation 
in AML blasts in response to BMSC conditioned media 
(CM). Figure 4B shows that BMSC CM induced pAKT 
(s473 and t308) activation is inhibited by IPI-145 at 
100nM. Since SDF1-CXCR4 axis has been described 
as an important mediator of AML migration [29], we 
analysed the effect of increasing concentrations of IPI-145 
treatment on SDF1 induced AML migration. Figure 4C 
shows that IPI-145 inhibits SDF1 induced AML migration 
in a dose dependent manner. Figure 4D shows that IPI-145 
did not inhibit SDF1-induced CD34+ migration. Figure 4E 
shows that the AKT inhibitor MK2206 had no effect on 
SDF1-induced AML blast migration. These results show 
that PI3Kδ and PI3Kγ regulate AML cellular migration in 
response to factors secreted by BMSC and furthermore 
that blast migration can be blocked by IPI-145 through its 
inhibitory effect on phosphorylation of AKT at t308.
PI3Kδ modulates adhesion and proliferation 
and PI3Kγ modulates adhesion, proliferation 
and migration in human AML
We next evaluated the genetic inhibition of PI3Kδ 
and PI3Kγ using shRNA in OCI-AML3. To do this 
we generated lentivirus-mediated PI3Kδ and PI3Kγ 
knockdowns. These constructs induced PI3Kδ and PI3Kγ 
knockdown confirmed for up to 7 days by real-time PCR 
(Figure 5A). Using these constructs the role of PI3Kδ and 
PI3Kγ in cell viability was assessed. The introduction of 
PI3Kδ shRNA inhibited the proliferation of OCI-AML3 at 
three and seven days post infection (Figure 5B), while the 
introduction of PI3Kγ shRNA inhibited the proliferation 
of OCI-AML3 only seven days post infection (Figure 5B). 
CellTiterGlo was also used to determine cell viability of 
OCI-AML3 transduced with either PI3Kδ or PI3Kγ 
knockdown and showed a similar result to the cell count 
data (data not shown). When we analysed the role of 
PI3Kδ and PI3Kγ in AML adhesion assays we also found 
that both isoforms did not inhibit AML adhesion to BMSC 
(Figure 5C). Next we examined migration and found 
that only PI3Kγ shRNA inhibited the migration of AML 
to SDF-1 (Figure 5D). Finally we assessed the effect of 
PI3Kδ and PI3Kγ inhibition on AKT activity. Both PI3Kδ 
and PI3Kγ shRNA inhibited AKT-s473, whilst PI3Kγ 
shRNA could also inhibit t308 phosphorylation (Figure 
5E). Together these studies define distinct functions of 
PI3Kδ and PI3Kγ isoforms in AML.
DISCUSSION
Despite the recognition that AML represents a 
morphologically and genetically diverse collection of 
tumours it is also apparent that these tumours rely on 
common programs of self-renewal. The PI3K/AKT 
pathway is known to be constitutively active in 50-80% 
of patients with AML and is associated with overall 
decreased survival [15, 30]. Accordingly the PI3K/AKT 
pathway may represent a valid therapeutic target which 
could prove applicable and effective in broad populations 
of patients with AML.
It has been reported that AML proliferation and 
survival can be inhibited by the pan PI3K inhibitor LY 
294002 [13]. Moreover, reports show that idelalisib 
(PI3Kδ inhibitor) shows little or no inhibitory effect on 
AML [31]. This suggests that PI3K p110 driven pro-
survival signalling is isoform specific. In this study we 
observe that both PI3Kδ and PI3Kγ are ubiquitously 
expressed in AML cell lines and AML blasts. We further 
demonstrate that inhibiting PI3K with LY294002 reduces 
the survival of all AML cell lines tested, however 
LY294002 is not suitable for use as a clinical drug due 
to its high levels of toxicity in-vivo. Moreover, inhibiting 
both PI3Kδ and PI3Kγ using IPI-145 demonstrates a 
greater inhibitory effect in AML cell lines compared to 
inhibiting PI3Kδ alone. Furthermore, when we examine 
the effect of IPI-145 on primary AML blasts we confirm 
that we can inhibit survival and colony formation at doses 
that are reportedly achievable in vivo [24, 25].
In non-malignant myeloid cells both PI3Kδ and 
PI3Kγ have distinct roles. For example, in mast cells 
PI3Kδ is required for activation by SCF and IL-3, which 
induces mast cell proliferation and adhesion [32], while 
PI3Kγ activation controls chemokine mediated GPCR 
activation and as such is an essential amplifier of mast 
cell function [33]. In AML, the mechanisms leading to 
PI3K/AKT activation are not yet clear. It is known that 
activation of receptor tyrosine kinases (RTK) expressed 
on the cell surface of AML have been shown to lead 
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Figure 4: IPI-145 inhibits AML migration to BMSC. A. Primary AML blasts were pre-treated with IPI-145 and then Calcein-AM 
was added at 2.5μM for 1 hour, then washed off. The cells were then placed in the upper well of a 5.0μM transwell plate. The lower chamber 
contained normal media (NM) or BMSC conditioned media (CM). Cells were incubated for 3 hours and then assessed using a fluorescent 
plate reader. B. Primary AML blasts (AML#2 and AML#5) were treated with increasing doses of IPI-145 and cultured for 4 hours. They 
were then incubated with BMSC conditioned media for 5 minutes. Whole cell extracts were prepared and Western blot analysis was 
conducted for pAKT (s473 and t308) and total AKT, as well as pMAPK and total MAPK C. Primary AML blasts (AML#2) and AML cell 
line (OCI-AML3) were pre-treated with IPI-145; Calcein-AM was added at 2.5μM for 1 hour, then washed off. The cells were then placed 
in the upper well of a 5.0μM transwell plate. The lower chamber contained increasing doses of SDF1. Cells were incubated for 3 hours and 
then assessed using fluorescent plate reader. D. CD34+ hematopoietic stem cells were pre-treated with IPI-145 and then Calcein-AM was 
added at 2.5μM for 1 hour, then washed off. The cells were then placed in the upper well of a 5.0μM transwell plate. The lower chamber 
contained increasing doses of SDF1. Cells were incubated for 3 hours and then assessed using fluorescent plate reader. E. Primary AML 
blasts were pre-treated with IPI-145 (1000nM) or MK2206 (1000nM) for 30 mins and then Calcein-AM was added at 2.5μM for 1 hour, 
then washed off. The cells were then placed in the upper well of a 5.0μM transwell plate. The lower chamber contained increasing doses of 
SDF1. Cells were incubated for 3 hours and then assessed using fluorescent plate reader. For all results in this figure except (B( a two-way 
ANOVA with Sidak’s post test was used. Results with P < 0.05 were considered statistically significant (*).
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Figure 5: shRNA knockdown of PI3Kδ and PI3Kγ. A. AML cell line (OCI-AML3) was transduced with either PI3Kδ or PI3Kγ-
targeted shRNA or a negative-targeted shRNA lentiviral construct for 72 h. RNA was extracted and assessed for PI3Kδ and PI3Kγ mRNA 
by real-time PCR. mRNA expression was normalized to GAPDH mRNA levels (n=4). B. OCI-AML3 was transduced with either PI3Kδ 
or PI3Kγ-targeted shRNA lentivirus for up to 7 days. Cell numbers were measured and expressed as a percentage of control transfected 
cells. C. OCI-AML3 was transduced with either PI3Kδ or PI3Kγ-targeted shRNA lentivirus for 72 h. Calcein-AM was added at 2.5μM for 
1 hour, then washed off. The cells were then cultured on top of primary BMSC for 4 hours. Non-adherent cells were removed with gentle 
washing. Adherent cells were measured using fluorescence plate reader. Cell adhesion was then assessed and expressed as percentage of 
total cells in the assay. D. OCI-AML3 were transduced with either PI3Kδ or PI3Kγ-targeted shRNA lentivirus for 72 h and then placed 
in the upper well of a 5.0µM transwell plate. The lower chamber contained 500ul of serum free media supplemented with SDF1 (100 ng/
ml) for 3 hours; we then assessed cell numbers using a flow cytometer. Data were normalised to control-KD cells. E. OCI-AML3 were 
transduced with either PI3Kδ or PI3Kγ-targeted shRNA lentivirus for 72 h and then protein was extracted and analysed for pAKT (s473 
and t308) and total AKT using Western blotting. * indicates those results which are statistically significant (P-value <0.05), comparing the 
KD samples to the control KD.
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to downstream AKT phosphorylation [18, 19, 34]. 
Moreover, others have shown that activation of GPCR 
on AML lead to downstream AKT phosphorylation [35, 
36]. What has not been described is the specific PI3K 
isoform/s that are responsible for the different models 
of activation of either RTK or GPCR. In addition, there 
is no data describing which AKT phosphorylation sites 
are activated by RTK or GPCR in AML. Here using 
shRNA knockdown and IPI-145 we show that PI3Kδ and 
PI3Kγ together control the proliferation signals in human 
AML, whereas PI3Kγ alone controls the GPCR regulated 
migration signalling.
AKT phosphorylation on s473 can be detected in up 
to 80% of AML patients while the information on AKT 
phosphorylation on t308 is less well characterised. A study 
by Gallay et al (2009), showed that 24 out of 53 AML 
patients had high AKT phosphorylation on t308 and this 
(but not AKT phosphorylation on s473) was associated 
with high-risk cytogenetics and predicted poor overall 
survival in AML [37]. Our results show that IPI-145 can 
inhibit constitutive AKT phosphorylation on both s473 
and t308. Moreover we also show that conditioned media 
from BMSC induced AKT phosphorylation on both s473 
and t308 which was inhibited by IPI-145. These data 
demonstrate that in-vitro IPI-145 can inhibit BMSC-
mediated AKT phosphorylation at both s473 and t308 in 
primary AML blasts.
The interactions between tumour and its bone 
marrow microenvironment have an important role in 
regulating the survival and proliferation of AML blasts. 
We have shown that inhibition of PI3Kδ and PI3Kγ can 
disrupt adhesion of AML blasts to BMSC and fibronectin, 
and that pre-treatment with IPI-145 can overcome the 
chemotherapy resistance which BMSC have been shown 
to provide to AML blasts. Overall we have shown an 
important role for PI3K and downstream signalling 
in the AML / BMSC pro-survival interaction. As such 
we provide data that support the clinical evaluation of 




Anti-phosphorylated and pan, AKT, and MAPK 
antibodies, as well as PI3Kγ were purchased from 
Cell Signalling Technology (Cambridge, MA, USA). 
Anti-CD34-PE, anti-CD90-FITC, anti-CD73-PE, 
anti-CD105-APC antibodies as well as SDF-1 were 
purchased from Miltenyi Biotec (Auburn, CA, USA). 
Anti-PI3Kδ antibody was purchased from R&D 
systems (Abingdon, UK). LY294002, CAL101, IPI-145, 
MK2206 and AZD6224 were obtained from Selleck 
Chemicals (Tx, USA). All other reagents were obtained 
from Sigma-Aldrich (St Louis, MO, USA), unless 
indicated.
Methods
Cell lines and primary cells
The AML-derived cell lines were obtained from 
the European Collection of Cell Cultures and DMSZ 
where they are authenticated by DNA-fingerprinting. In 
the laboratory they are used at low passage number for 
a maximum of six months post-resuscitation, testing 
regularly for Mycoplasma infection. AML blasts 
were obtained from patients’ bone marrow or blood 
following informed consent and under approval from 
the UK National Research Ethics Service (LRECref07/
H0310/146) Table 1. For primary cell isolation, 
heparinized blood was collected from volunteers and 
human peripheral blood mononuclear cells (PBMCs) 
isolated by Histopaque (Sigma-Aldrich) density gradient 
centrifugation. AML samples that were less than 80% 
blasts were purified using the CD34 positive selection kit.
Human bone marrow stromal cells (BMSC) 
were isolated by bone marrow aspirates from AML 
patients. Mononuclear cells were collected by gradient 
centrifugation and plated in growth medium containing 
DMEM and 20% FBS and 1% l-glutamine. The non-
adherent cells were removed after 2 days. When 60%-80% 
confluent, adherent cells were trypsinised and expanded 
for 3-5 weeks. BMSCs were checked for positive 
expression of CD105, CD73, and CD90 and the lack 
of expression of CD45 and CD34 by flow cytometry as 
previously described [38].
Western immunoblotting
Sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis and Western blot analyses were performed 
as described previously. Briefly, whole cell lysates were 
extracted and sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis separation performed [39]. Protein was 
transferred to nitrocellulose and Western blot analysis 
performed with the indicated antisera according to their 
manufacturer’s guidelines.
Proliferation and apoptosis
Cells were treated with different doses of IPI-
145 then viable numbers measured with Cell TiterGlo 
(Promega, Southampton, UK). For the AML-BMSC co-
cultures AML cell viability was measured using trypan 
blue exclusion.
Clonogenic methylcellulose assays
Control CD34+ HSC and primary AML cells (1×103 
to 5×104 cells) were plated in methylcellulose medium 
(R&D systems) and colonies were visualised, measured 
and counted after 10 days. For normal CD34+ CFU-GM, 
CFU-M, CFU-M and BFU-E was measured.
Migration assays
Migration assays were performed in triplicate in 
transwell permeable plates with 5.0µM pores (Neuroprobe, 
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MD, USA). The lower compartment contained 30µL of 
conditioned media or serum free media supplemented with 
100 ng/ml SDF1 and the cells were applied to the upper 
compartment and allowed to migrate for 3 h. The amount 
of viable migrated cells was determined by counting using 
trypan blue exclusion and expressed as a percentage of 
the input.
BMSC/fibronectin-AML cell adhesion assay
BMSCs were grown in 96-well plates. Primary 
AML cells were incubated with 2.5 µM calcein-AM for 
1 h at 37°C and 5% CO2. The fluorescence-labelled AML 
cells were added into stromal cell coated 96-well plates 
and incubated for the indicated time points. Non-adherent 
calcein-labelled cells were removed by gently washing 
and adherent cells were quantified in a fluorescence multi-
well plate reader. For AML blast adhesion onto fibronectin 
(FN), 96 well plates were coated with 10 mg/ml FN for 1 
h before the fluorescence-labelled AML cells were added. 
Again non-adherent calcein-labelled cells were removed 
by gently washing and adherent cells were quantitated in 
a fluorescence multi-well plate reader.
RNA extraction and real-time PCR
Total RNA was extracted from 5 x 105 cells using 
the Nucleic acid Prep Station from Applied Biosystems 
(Paisley, UK), according to the manufacturer’s 
instructions. Reverse transcription was performed using 
the RNA polymerase chain reaction (PCR) core kit 
(Applied Biosystems). Relative quantitative real-time 
PCR used SYBR green technology (Roche, Burgess Hill, 
UK) on cDNA generated from the reverse transcription 
of purified RNA. After pre-amplification (95°C for 2 
minutes), the PCRs were amplified for 45 cycles (95°C 
for 15 seconds and 60°C for 10 seconds and 72°C for 10 
seconds) on a 384-well LightCycler 480 (Roche). Each 
mRNA expression was normalized against GAPDH 
mRNA expression using the standard curve method.
Transfections
OCI-AML3 were plated onto 12 well plates at 5 x 
104 cells/well/0.5ml. Cells were infected with lentiviral 
stocks at an MOI of 15 in the presence of 8 μg/ml 
Polybrene. Transduced cells were analysed by real-time-
PCR (Roche).
Statistical analyses
We used the Mann-Whitney U test to compare results 
in control to treated groups. Results with P < 0.05 were 
considered statistically significant (*). We also use the Two-
way ANOVA with Sidak’s post test. Results with P < 0.05 
were considered statistically significant (*). Results represent 
the mean ± SD of 4 independent experiments. For Western 
blotting, data are representative images of 3 independent 
experiments. We generated statistics with Graphpad Prism 5 
software (Graphpad, San Diego, CA, USA).
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Table 1: AML Sample information
ID Age Sex WHO classification Cytogenetics
AML #1 70 m AML with minimal differentiation Normal
AML #2 40 m AML with minimal differentiation Normal
AML #3 91 f AML NOS Not available
AML #4 59 f AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 t(8;21)
AML #5 51 m AML with monocytic differentiation pending
AML #6 65 m AML with minimal differentiation Normal
AML #7 23 f AML without maturation t(5;12)
AML #8 65 m AML with maturation Trisomy 13
AML #9 37 m AML without maturation Normal
AML #10 65 m AML with maturation Not available
AML #11 68 m Therapy related AML Not available
AML#12 63 m AML with MDS related changes Not available
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